Quantitative estimation of catechol/methylcatechol pathways in human phenytoin metabolism

Area of Science:

• Pharmacokinetics
• Analytical Chemistry
• Metabolism Studies

Background:

• Phenytoin (PHT) is an anticonvulsant medication with complex metabolism.
• Understanding PHT metabolic pathways is crucial for therapeutic drug monitoring and toxicity assessment.
• The catechol/MCAT pathway represents one route of PHT metabolism, but its quantitative significance is not fully established.

Purpose of the Study:

• To develop and validate a sensitive gas-liquid chromatographic (GLC) assay for quantifying 5-(4-hydroxy-3-methoxyphenyl)-5-phenylhydantoin (MCAT) in human urine.
• To determine the percentage of a daily phenytoin (PHT) dose excreted as MCAT in patients undergoing chronic PHT therapy.
• To investigate the relationship between urinary MCAT levels and other known PHT metabolites, specifically dihydrodiol (DHD) and p-phenolic (p-HPPH).

Main Methods:

• Development of a gas-liquid chromatographic (GLC) assay with on-column methylation for MCAT detection.
• Assay of MCAT concentrations in 35 samples of 24-hour urine collected from patients on chronic PHT treatment.
• Application of multiple regression analysis to correlate MCAT levels with DHD and p-HPPH metabolite quantities.

Main Results:

• The developed GLC assay demonstrated specificity for MCAT.
• Urinary MCAT accounted for 0.3-4.0% of the daily PHT dose administered to patients.
• Multiple regression analysis revealed a significant dependence of urinary MCAT levels on the concentrations of both DHD and p-HPPH metabolites.

Conclusions:

• The GLC assay provides a reliable method for quantifying the PHT metabolite MCAT in urine.
• The catechol/MCAT metabolic pathway accounts for a small but measurable fraction of the total PHT dose.
• Oxidative metabolism of DHD and p-HPPH are likely precursors to the formation of catechol/MCAT, indicating interconnected PHT metabolic pathways.